What does this research mean for the field?

The global direct annual cost of coronary heart disease per patient is substantial, averaging 21.7% of GDP per capita, with significant variations by region and a slightly higher cost burden in men. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

January 1, 2025BMJ Open14 citationsOpen Access

Global comparison of the economic costs of coronary heart disease: a systematic review and meta-analysis

SSSangita ShakyaNepal Medical College Teaching Hospital ASAnita ShresthaManmohan Memorial Institute of Health Sciences SRSuzanne RobinsonDeakin University

Structured PICO

Population

2,564,189 adults with coronary heart disease (CHD) pooled from 37 observational studies across 22 countries

Outcome

Economic costs of CHD treatment (pooled direct annual cost of CHD per patient as a percentage of GDP per capita)

The global economic burden of coronary heart disease is substantial, with the pooled direct annual cost per patient equating to 21.7% of GDP per capita.

Abstract

OBJECTIVES: Coronary heart disease (CHD) is the leading cause of global morbidity and mortality, yet no comprehensive evaluation of its global economic costs exists. We conducted a systematic review with meta-analysis to examine the costs of CHD treatment by region and CHD subtypes, examine whether there are cost difference by sex, and examine costing methodologies. DESIGN: We conducted a systematic review and meta-analysis of non-randomised studies. DATA SOURCES: We searched Medline, Embase, CINAHL, EconLit and Google Scholar from 1 January 2000 to February 2023. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included observational studies reporting economic costs of CHD treatment and outcomes for adults that were published in English. DATA EXTRACTION AND SYNTHESIS: statistic. Meta-regression and bias assessment were performed. RESULTS: Out of 20 100 records identified, 37 studies (including 2 564 189 individuals) from 22 countries were included in the qualitative synthesis and the quantitative meta-analysis. In most countries, the annual cost of CHD exceeds many times the total health expenditure per capita. The pooled direct annual cost of CHD per patient varied from 4. 9% to 137. 8% of GDP per capita (Int purchasing power parity), with pooled percentage of 21. 7% (95% CI 15. 3, 28. 1) for those with CHD. Slight difference in the annual pooled cost of CHD was observed, with a 2% of GDP per capita higher cost in men (95% CI 0. 8, 3. 2). Most studies applied a top-down costing approach (n=21). CONCLUSIONS: The review illustrates the expense associated with CHD, which is varied by region and CHD subtypes. The observed cost difference by sex warrants further exploration of sex-specific factors influencing cost disparities. Exploring advanced costing methods such as time-driven activity-based costing can optimise resource allocation and identify opportunities to reduce unnecessary costs and cost disparities. PROSPERO REGISTRATION NUMBER: CRD42023412044.

Ask AI

Helpful

Bookmark

View Full Paper